Industry Overview: The Convergence of Wellness and Aesthetics

The U.S. medical spa and aesthetic clinic sector has entered 2026 as one of the most resilient verticals in all of healthcare services. As of Q1 2026, the market sits between $24.4B and $26.2B, growing at a 14.3% compound annual growth rate. Industry forecasts put the total addressable market near $49.8B by 2030.

What changed is demand composition. Aesthetic maintenance has moved from a discretionary luxury into the recurring line item of a consumer's wellness budget. Two demographic engines drive this: the aging Baby Boomer and Gen X populations seeking longevity and rejuvenation, and the "Prejuvenation" wave among Millennials and Gen Z treating cosmetic care as preventative. Men are the fastest-growing segment, compounding at 15.94%, while women still represent 71.3% of total revenue.

The GLP-1 Secondary Wave

By April 2026, an estimated 31 million Americans are using GLP-1 medications (semaglutide, tirzepatide). That has created a massive secondary wave of demand for skin tightening, facial fillers, and fat grafting to address volume loss from rapid weight reduction. Clinics that have built protocols around this transition are capturing higher average transaction values and better retention than traditional injectable-only practices.

The Market Is Still Fragmented, But Not for Long

As of 2024, roughly 66% of med spas were under single ownership. That ratio is collapsing fast. Private equity platforms and strategic dermatology and plastic surgery groups are aggressively rolling up regional density, and the window for an independent owner to sell into a competitive buyer pool is wider today than it will likely be in three years.

M&A Activity and Deal Trends

The 24 months leading into Q1 2026 have defined what we call a "Platform and Add-On Super-Cycle." Mega-buyouts have cooled under antitrust scrutiny, but the lower-middle market, specifically practices with revenue between $500K and $10M, has seen record transaction velocity. Private equity firms are deploying dry powder into smaller, regulatory-safe add-ons to build regional density before a larger strategic exit.

What Buyers Are Actually Buying

Acquirers are no longer buying revenue. They are buying infrastructure. Strategic buyers led 86% of 2025 transactions, focusing on "adjacency stacking": adding med spa services to existing dermatology or plastic surgery platforms to capture the entire patient lifecycle, from insurance-based medical care through cash-pay cosmetic.

Notable Recent Transactions

Buyer Landscape: What Each Buyer Type Actually Wants

The buyer pool in 2026 has matured. Where 2021 was about growth at all costs, 2026 is about operational resilience. Understanding what each buyer type actually rewards is the difference between an average offer and a premium one.

EBITDA and SDE Floors

Most institutional buyers will not engage below $1M in normalized EBITDA. Below that threshold, the pool shifts to individual buyers and search funds valuing the business on Seller's Discretionary Earnings (SDE) rather than EBITDA. The practical implication: crossing the $1M EBITDA line expands your buyer pool by roughly 3x and meaningfully raises your achievable multiple.

Financial Benchmarks: What a "Clean" Med Spa Looks Like

Med spas vary widely in margin profile depending on service mix, provider model, and owner dependency. These are the benchmarks buyers and lenders use in 2026.

Revenue and Margin Benchmarks

Overhead Ratios That Lenders Watch

Lenders and sophisticated buyers benchmark operating overhead (excluding physician compensation) at 55% to 65%. Above 70% is a red flag for inefficiency. Below 55% often signals underinvestment in staff, safety, or facility. Revenue per provider sits at a lender benchmark of roughly $300K or more per year. Below that raises questions about volume, scheduling efficiency, or fee schedule.

Valuation Multiples: The Honest Range

Valuations in 2026 are not uniform. We think about med spa valuations in three bands, and the band you fall into is determined almost entirely by scale, owner dependency, and the transition from SDE to normalized EBITDA.

The $1M EBITDA Graduation Zone

Below $1M in EBITDA, buyers treat the practice as a job purchase. Valuation happens on a multiple of SDE and the buyer pool is primarily individuals and search funds. Once a practice clears $1M to $3M in EBITDA, it enters the Graduation Zone: valuation shifts to a multiple of normalized EBITDA and the buyer pool expands to include institutional investors and PE platforms.

Revenue Multiples for Smaller Practices

For practices with $1M to $10M in revenue that do not yet have the EBITDA profile for a traditional multiple, the market supports revenue-based multiples in the following ranges:

• $1M to $5M revenue: 1.5x to 2.6x, with consistency and repeat rates driving the high end.
• $6M to $10M revenue: 2.5x to 3.5x, with brand equity and multi-market presence at the top.
• Premium platforms: 4.0x+, reserved for proprietary protocols or GLP-1 specialization.

What Moves the Multiple Up

Premium multiples are earned through recurring membership revenue (30 to 40% of total revenue), low owner dependence, multiple credentialed injectors, clean MSO/PC compliance structure, transferable patient relationships, and clinical SOPs that a new owner can actually operate. Clinics with specialized GLP-1 wellness integration are currently the most sought-after assets in the category, with patient retention in the 85 to 90% range over 18 months.

What Compresses the Multiple

Owner-centric operations where the founder is the primary injector. Paper medical directors who receive a stipend but show no real oversight. CPOM violations from operating as a standard LLC in states like California, New York, or Texas without a "Friendly PC" structure. Unlicensed practice. Data silos across multiple software systems. Aggressive add-backs without documentation. Any of these on their own will compress the multiple. Stacked, they kill the deal.

SBA Lending and Deal Financing

Med spas are generally eligible for SBA 7(a) financing, but the lending environment in Q2 2026 is rigorous. The Fed's "higher for longer" stance has held rates up, and lenders are underwriting operational quality as much as historical financials.

Current SBA 7(a) Rate Environment

The Wall Street Journal Prime Rate sits at 6.75% as of April 2026, which remains the most common base for aesthetic clinic acquisitions. The SBA Optional Peg Rate for Q2 2026 is 4.50%, offering a more favorable alternative for certain variable-rate loans.

What Lenders Actually Require

Typical buyer down payment is 10% for SBA-backed transactions. Lenders require a minimum Debt Service Coverage Ratio (DSCR) of 1.25x, though Atlantic Coast advises structuring deals to a 1.4x minimum to give the buyer operational cushion. Seller notes of 10 to 20% of purchase price are standard and often required by the lender.

Typical Deal Structure in 2026

Lower-middle market med spa transactions rarely close at 100% cash. The typical structure:

Timing and Market Outlook

If you are considering an exit, 2026 is a unique window. Three forces are stacked in favor of sellers right now, and at least two of them will not be stacked this way in 2028.

1. The PE Exit Pressure

Private equity platforms that consolidated between 2016 and 2020 are reaching their 5 to 7 year maturity. These platforms need their next liquidity event, and they are buying add-ons aggressively in Q1 and Q2 2026 to bulk up EBITDA before a year-end or 2027 sale. That urgency translates into competitive bidding for quality independent practices.

2. The Regulatory Grace Period

California's SB 351 and New York's Med Spa Task Force are active and expanding. Many other states are still in the legislative study phase. Sellers who exit in 2026 can capitalize on high multiples before more restrictive "mini-HSR" style laws, which require 90-day notices for even small transactions, become a national standard. The compliance premium that buyers pay today for a clean MSO structure may be priced in as baseline expectation by 2028.

3. The GLP-1 Second Wave Peak

The "Ozempic face" demand surge is at its peak. Clinics are seeing a record influx of first-time patients highly motivated to spend on skin tightening, fillers, and volume restoration. This surge has inflated TTM revenue for many clinics, creating an ideal valuation baseline for a 2026 exit. That effect normalizes over time as the patient pipeline matures.